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Antimicrobial studiesAbstract The paper describes the facile synthesis of new N-cyclopropyl-1-methyl-1H-indole-2-
carboxamide derivatives bearing substituted 2-amino pyrimidine moiety at position-3 of the indole
ring. All the intermediate and title compounds were characterized adeptly by 1H NMR, 13C NMR,
ESI–MS and elemental analyses. These compounds were evaluated for their in vitro anticancer
activity against HeLa, HepG2 and MCF-7 cells. Three among 22 molecules, showed more than
70% growth inhibition against all three tested cancer cells. The nature of the substituent group
on the pyrimidine ring (R2) affected signiﬁcantly the anti-proliferative activity of the molecules.
The anti-microbial evaluation of the title molecules revealed the signiﬁcance of ﬂuoro/chloro groups
(R2) in enhancing their inhibition activity. Eight molecules which contain ﬂuoro/chloro groups
showed potent anti-microbial activity. In addition, the active molecules displayed negligible toxicity
to benign Vero cells.
 2015 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The term ‘cancer’ encompasses an extensive range of malignan-
cies and is currently the leading cause of death in developed
countries and comes second in developing countries [1]. Afﬂic-
tion due to cancer is increasing exponentially owing to its
innate characteristics viz. uncontrolled proliferation, invasion
and metastasis. Its treatment remains an important and chal-
lenging therapeutic task in the ﬁeld of medicinal chemistry since
majority of the tumours are either not completely curable or fail
to respond to chemotherapy. Although infections by drug-
sensitive strains can be successfully cured, the emergence ofy, Jour-
2 N. Gokhale et al.drug resistance has prompted the discovery and development of
new, more active and less toxic anti-tumour drugs. Heterocyclic
motifs are of immense biological interest due to their occur-
rence in many natural products and their varied physico-
chemical properties. Various classes of such heterocycles with
diverse chemical structures are used as chemotherapeutic
agents or are under clinical trials. Amidst all of them, we have
chosen the indole unit as a lead molecule because the
3-substituted indoles, in particular, have proven to be versatile
intermediates for the synthesis of a wide range of bioactive
drugs [2–4]. Further, literature survey reveals that a combina-
tion of two or more active structural moieties can possibly
augment the bioactivity. A variety of N-based heterocycles
viz. pyridine [5], quinolone [6], quinazoline [7], etc. have been
integrated with the indole nucleus to get potent molecules.
Leading amongst them is the pyrimidine ring system which
has a distinguished account starting from its discovery phase
as a constituent of nucleic acids to their present-day use in
chemotherapy [8]. The pyrimidine ring is found in vitamins like
thiamine, riboﬂavin and folic acid [9]. One of the early anti-
metabolite 5-ﬂuorouracil, a pyrimidine derivative, is used as
an anti-neoplastic agent [9]. Over the years, pyrimidine ring sys-
tems have been widely explored for their diverse range of bio-
logical activities [10–15]. In addition, many pyrimidine
analogues have been developed as chemotherapeutic agents
[16], anti-leukaemic drugs [17], calcium-sensing receptor antag-
onists [18], etc. It will be interesting to see indole and pyrimidine
moieties, which are considered to be potent pharmacophores
on their own, to be incorporated into a single structural entity
for better efﬁcacy in terms of their pharmacological activity.
As reviewed from earlier literature reports, efforts have
been made to assimilate indole and pyrimidine analogues to
afford novel chemical entities with appreciable biological
activity. Most of them either had a carbonyl group or its ana-
logue thiocarbonyl at position-2 of the pyrimidine heterocycle
and an unsubstituted N–H group on the indole as well as on
the pyrimidine unit. Such compounds were found to be potent
as antitumour [19,20], antimicrobial [21,22] and antioxidant
[23] agents. Moreover, meridianins viz. marine indole alkaloids
(comprising of indole units bearing 2-amino pyrimidine ring)
from tunicate Aplidium meridianum have also been isolated
and their total synthesis was carried out (Fig. 1) [24,25]. These
natural products not only exhibit cytotoxicity but also inhibit
CDKs, GSK-3, PKA and other protein kinases [26]. Further,
some derivatives of meridianins have shown excellent inhibi-
tion against MCF-7 and HeLa cells [27]. Also, pyrimidine hete-
rocycles possessing a free amine group at position-2 of the ring
have acquired a unique place in medicinal chemistry. In fact,
the 2-amino group is a common structural feature in someHN
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Figure 1 Structures of some indole and pyrimidine based
bioactive molecules.
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amide moiety at the position-2 of indole enhanced the anti-
proliferative effect by HDAC (histone deacetylase) inhibition
activity as compared to its substitution at other positions of
the indole ring [29]. Based on these facts, we envisaged them
to be effective substitutes for esters in improving the potency
of synthesized compounds. In the case of amides, the
cycloalkyl [30] moiety was chosen as it is considered to be an
isostere of oleﬁn [31]. Besides, a cyclopropyl group could be
used in SAR studies in place of a geminal-dimethyl group or
a geminal-diﬂuoro group. A cyclopropyl group may also pro-
vide metabolic stability because of its inherent bond angle
leading to enhanced activity of the synthesized molecules [31]
prompting us to incorporate a cyclopropyl amide moiety at
position-2 of the indole ring. Hence, in the ongoing search
for potent chemical entities and with reference to the aforesaid
facts, we aimed to synthesize molecules comprising of these
two pharmacophores in a single molecular framework. In view
of this, a new library of indole-pyrimidine hybrids were pre-
pared by the cyclization of indole-3-chalcones. In addition,
the bioisosteric replacement of hydrogen by ﬂuorine [32] at
position-5 and ester by amide linkage at position-2 of indole
nucleus [29,30] was also carried out for improving the biolog-
ical potency of the synthesized molecules. All the title com-
pounds were investigated for their anti-cancer activity over
three human cancer cell lines, by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. In addition,
we have tested these molecules for their antimicrobial activity
as well against a few strains of bacteria and fungi.
2. Experimental
2.1. Materials and methods
All the chemicals used in the present work were procured from
Sigma Aldrich (Germany) and Spectrochem Chemicals Pvt.
Ltd. All the solvents used are of analytical grade. They were
purchased, distilled and dried before their usage. The progress
of the reaction was monitored by thin layer chromatography,
performed on a Silica gel 60 F254 coated aluminium sheet.
Melting points were determined on open capillaries using a
Stuart SMP3 (BIBBY STERLIN Ltd. UK) apparatus and
were uncorrected. IR spectra were recorded on a Bruker Alpha
Eco-ATR spectrometer as neat sample. The 1H NMR spectra
of the intermediates and ﬁnal compounds were recorded with a
Bruker 400 MHz NMR spectrometer using TMS as internal
reference and DMSO-d6 as the solvent. The
13C NMR spectra
of the compounds were recorded using a Bruker 100 MHz
NMR spectrometer. Elemental analyses were performed on a
Flash EA-1112 CHNS analyzer (Thermo Electron Corpora-
tion). Mass spectra were recorded on Agilent Triple quad
LC–MS model: 0430, using methanol as the solvent. All the
reactions, except for the hydrolysis step, were performed under
strict inert conditions.
2.2. Synthesis
2.2.1. Procedure for synthesis of ethyl 1-methyl-1H-indole-2-
carboxylate (5a)
The ethyl 1H-indole-2-carboxylate intermediate 4a (6 g,
31.71 mmol) was suspended in anhydrous dimethyl formamidedine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Synthesis and evaluation of indole-pyrimidine hybrids 3(DMF) (60 mL) in a dry round bottomed ﬂask to which
potassium carbonate (8.7 g, 52.85 mmol) was added at 0 C.
Tetra-n-butylammonium bromide (n-TBAB) was added in
catalytic amount to this mixture. It was then stirred at room
temperature for 30 min following which methyl iodide (6 mL,
95.13 mmol) was added. The reaction mass was then kept for
stirring for 12 h. The progress of the reaction was monitored
using TLC. After the complete consumption of the starting
material, the reaction mass was poured into ice-cold water
and extracted using ethyl acetate. The organic layer was dried
over anhydrous sodium sulfate and evaporated under vacuum.
The crude product was puriﬁed using column chromatography
with pet ether/ethyl acetate to obtain the pure compound.
Yield: 5.4 g, 90%. Yellow crystalline solid, m.p. 55–56 C.
IR (neat, cm1): 2981, 1725, 1651, 1235, 1140, 1033. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 7.69–7.11 (m, 5H,
Ar-H), 4.32 (q, 2H, –CH2), 4.02 (s, 3H, N–CH3), 1.33 (t, 3H,
–CH3, J= 7.2 Hz).
13C NMR (DMSO-d6, 100 MHz, d
ppm): 161.8, 139.7, 128.1, 125.8, 125.3, 122.7, 121.0, 111.3,
110.0, 60.8, 32.0, 14.7. MS: m/z= 204.2 (M+H). Anal. Calcd.
for C12H13NO2: C, 70.92; H, 6.45; N, 6.89. Found: C, 70.90;
H, 6.39; N, 6.85.
2.2.2. Procedure for synthesis of ethyl 5-fluoro-1-methyl-1H-
indole-2-carboxylate (5b)
Intermediate 5b was prepared by treating compound 4b (6 g,
28.95 mmol) with a catalytic amount of n-TBAB, potassium
carbonate (8 g, 57.91 mmol) and methyl iodide (5.6 mL,
86.87 mmol) in DMF (60 mL) by following the above men-
tioned procedure. Yield: 5.1 g, 85%. Orange crystalline solid,
m.p. 73–74 C. IR (neat, cm1): 2985, 1720, 1648, 1232,
1149, 1030. 1H NMR (DMSO-d6, 400 MHz, d in ppm): 7.66–
7.10 (m, 4H, Ar-H), 4.22 (q, 2H, –CH2), 4.01 (s, 3H, N–
CH3), 1.30 (t, 3H, –CH3, J= 7.2 Hz).
13C NMR (DMSO-d6,
100 MHz, d ppm): 161.7, 138.0, 126.1, 125.8, 125.3, 122.7,
122.0, 111.3, 111.1, 63.0, 32.0, 14.7. MS: m/z= 222.2 (M
+H). Anal. Calcd. for C12H12FNO2: C, 65.15; H, 5.47; N,
6.33. Found: C, 65.11; H, 5.44; N, 6.29.
2.2.3. Procedure for the synthesis of 1-methyl-1H-indole-2-
carboxylic acid (6a)
The intermediate 5a (5 g, 24.60 mmol) was taken in MeOH:
THF (1:1) solvent mixture to which a solution of LiOH
(3 g, 73.80 mmol) in distilled water was added drop wise at
0 C. After the complete addition, the reaction mass was
stirred at RT for about 3 h. TLC showed the completion of
the reaction following which the solvent was removed in vac-
uum. Then, 10 mL distilled water was added to the residue,
after which the unreacted ester, if any, was removed by ether
extraction. The aqueous portion was then acidiﬁed using
50% HCl. The product precipitated on vigorous stirring was
ﬁltered off, washed with cold water and dried under vacuum.
This ﬁltered solid was pure and needed no further puriﬁcation.
Yield: 4.5 g, 90%. White solid, m.p. 208–209 C. IR (neat,
cm1): 2978, 1676, 1519, 1473, 1265, 1054, 1012, 730. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 10.6 (s, 1H, –OH),
7.68–7.10 (m, 5H, Ar-H), 3.98 (s, 3H, N–CH3).
13C NMR
(DMSO-d6, 100 MHz, d ppm): 163.5, 139.7, 129.0, 125.8,
125.1, 122.6, 120.8, 111.3, 109.9, 31.9. MS: m/z= 176.1 (M
+H). Anal. Calcd. for C10H9NO2: C, 68.56; H, 5.18; N,
8.00. Found: C, 68.51; H, 5.15; N, 7.98.Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
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indole-2-carboxylic acid (6b)
Intermediate 6b was prepared by treating compound 5b (4.9 g,
22.14 mmol) with LiOH (2.8 g, 66.44 mmol) in MeOH: THF
(1:1) mixture as per the above procedure. Yield: 4.3 g, 88%
Off-white solid, m.p. 262–263 C. IR (neat, cm1): 2981,
1676, 1520, 1473, 1271, 1238, 1054, 1013, 727. 1H NMR
(DMSO-d6, 400 MHz, d in ppm): 10.9 (s, 1H, –OH),
7.69–7.08 (m, 4H, Ar-H), 3.98 (s, 3H, N–CH3).
13C NMR
(DMSO-d6, 100 MHz, d ppm): 162.8, 158.8, 139.6, 135.5,
128.9, 114.4, 112.2, 112.2, 109.7, 31.9. MS: m/z= 194.2
(M+H). Anal. Calcd. for C10H8FNO2: C, 62.18; H, 4.17;
N, 7.25. Found: C, 62.14; H, 4.13; N, 7.21.
2.2.5. Procedure for the synthesis of N-cyclopropyl-1-methyl-
1H-indole-2-carboxamide (7a)
To a stirred solution of 6a (4.4 g, 25.11 mmol) in DMF
(44 mL), cyclopropyl amine (2.9 g, 50.23 mmol) was added
and the solution was cooled to 0 C. Coupling agent HATU
(10.5 g, 27.62 mmol) was added followed by the addition of
base, di-isopropylethyl amine (13 mL, 75.35 mmol) and the
reaction mixture was left for stirring for 16 h at RT. After
the completion of the reaction as monitored by TLC, the reac-
tion mixture was poured into ice-cold water and stirred well.
The precipitated product was then ﬁltered by suction, washed
with cold water, dried and weighed. It was then recrystallized
using ethanol. Yield: 4.1 g, 93%. White solid, m.p. 182–183 C.
IR (neat, cm1): 2977, 1628, 1534, 1458, 1278, 1053, 1009, 746.
1H NMR (DMSO-d6, 400 MHz, d in ppm): 8.47 (s, 1H, –NH),
7.61–7.02 (m, 5H, Ar-H), 3.97 (s, 3H, N–CH3), 2.85–2.83 (m,
1H, –CH), 0.72–0.56 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 163.5, 138.8, 132.6, 126.0, 123.9,
121.9, 120.5, 110.9, 104.8, 31.7, 23.2, 6.2. MS: m/z= 215.1
(M+H). Anal. Calcd. for C13H14N2O: C, 72.87; H, 6.59; N,
13.07. Found: C, 72.85; H, 6.55; N, 13.03.
2.2.6. Procedure for the synthesis of N-cyclopropyl-5-fluoro-1-
methyl-1H-indole-2-carboxamide (7b)
Intermediate 7b was prepared according to the above men-
tioned procedure by treating 6b (4.2 g, 21.74 mmol) with cyclo-
propyl amine (2.5 g, 43.48 mmol), HATU (9 g, 23.91 mmol)
and DIPEA (11 mL, 65.22 mmol) in DMF (42 mL). Yield:
3.9 g, 93%. Off-white solid, m.p. 172–173 C. IR (neat,
cm1): 2979, 1628, 1537, 1460, 1278, 1054, 1013, 747, 646.
1H NMR (DMSO-d6, 400 MHz, d in ppm): 8.49 (s, 1H,
–NH), 7.54–6.98 (m, 4H, Ar-H), 3.95 (s, 3H, N-CH3),
2.84–2.80 (m, 1H, –CH), 0.71–0.54 (m, 4H, aliphatic). 13C
NMR (DMSO-d6, 100 MHz, d ppm): 163.2, 159.0, 135.5,
134.1, 126.1, 112.3, 112.2, 112.2, 106.2, 32.0, 23.1, 6.2. MS:
m/z= 233.2 (M+H). Anal. Calcd. for C13H13FN2O: C,
67.23; H, 5.64; N, 12.06. Found: C, 67.19; H, 5.61; N, 12.01.
2.2.7. Procedure for the synthesis of N-cyclopropyl-3-formyl-1-
methyl-1H-indole-2-carboxamide (8a)
To a dried two-neck round bottom ﬂask containing DMF
(3 mL, 37.33 mmol), phosphorous oxychloride (POCl3)
(4 mL, 37.33 mmol) was added dropwise through a syringe
under argon at a temperature below 0 C. After the formation
of the iminium cation, a solution of intermediate 7a (4 g,
18.66 mmol) in DMF (40 mL) was added and the entireine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
4 N. Gokhale et al.reaction mass was heated at 60 C for 2 h. Reaction was mon-
itored using TLC and after the complete consumption of the
starting material, the reaction mixture was poured into crushed
ice and stirred well. The formed solid was collected by ﬁltra-
tion, washed with cold water, dried and used as such for the
next step. Yield: 3.7 g, 93%. Red solid, m.p. 160–161 C. IR
(neat, cm1): 2970, 2864, 1639, 1527, 1390, 1285, 1054, 1012,
835, 748. 1H NMR (DMSO-d6, 400 MHz, d in ppm): 9.92 (s,
1H, –CHO), 9.19 (s, 1H, –NH), 8.19–7.28 (m, 4H, Ar-H),
3.82 (s, 3H, N–CH3), 2.97–2.92 (m, 1H, –CH), 0.78–0.60 (m,
4H, aliphatic). 13C NMR (DMSO-d6, 100 MHz, d ppm):
184.0, 160.3, 143.0, 136.2, 124.0, 123.1, 122.7, 120.9, 113.9,
110.6, 30.8, 22.4, 5.3. MS: m/z= 243.3 (M+H). Anal. Calcd.
for C14H14N2O2: C, 69.41; H, 5.82; N, 11.56. Found: C, 69.38;
H, 5.79; N, 11.52.
2.2.8. Procedure for the synthesis of N-cyclopropyl-5-fluoro-3-
formyl-1-methyl-1H-indole-2-carboxamide (8b)
The above procedure was followed for the synthesis of 8b by
treating 7b (3.8 g, 16.36 mmol) with POCl3 (3 mL,
32.72 mmol) and DMF (2.5 mL, 32.72 mmol). Yield: 3.5 g,
92%. Olive green solid, m.p. 192–193 C. IR (neat, cm1):
2973, 2864, 1639, 1528, 1391, 1285, 1054, 1012, 836, 748,
645. 1H NMR (DMSO-d6, 400 MHz, d in ppm): 9.89 (s, 1H,
–CHO), 9.21 (s, 1H, –NH), 7.86–7.23 (m, 3H, Ar-H), 3.83 (s,
3H, N–CH3), 2.96–2.92 (m, 1H, –CH), 0.78–0.60 (m, 4H, ali-
phatic). 13C NMR (DMSO-d6, 100 MHz, d ppm): 185.1,
161.0, 158.6, 145.0, 134.0, 124.7, 124.6, 113.6, 113.6, 113.5,
32.2, 23.5, 6.3. MS: m/z= 261.1 (M+H). Anal. Calcd. for
C14H13FN2O2: C, 64.61; H, 5.03; N, 10.76. Found: C, 64.58;
H, 4.99; N, 10.71.
2.2.9. General Procedure for the synthesis of chalcone
intermediates (9a–v)
To a stirred ethanolic solution of required aromatic acetophe-
none in a dry round bottom ﬂask, 10% solution of NaOH in
ethanol was added and stirred at RT for 30 min. The formy-
lated intermediate 8a/8b (0.2 g) was then added to the reaction
mixture and stirring was continued for 2 h. Reaction comple-
tion was conﬁrmed by running TLC following which the pre-
cipitated solid was cooled adequately. The solid formed was
then ﬁltered under vacuum, washed with cold ethanol, dried
and recrystallized using ethanol. The obtained chalcone inter-
mediates 9a–v were suitably characterized and used as scaf-
folds for the ﬁnal step.
2.3. Structural characterization data of intermediates 9a–v
2.3.1. N-cyclopropyl-1-methyl-3-(3-oxo-3-phenylprop-1-enyl)-
1H-indole-2-carboxamide (9a)
Yield: 0.16 g, 80%. Pale yellow solid, m.p. 181–182 C. IR
(neat, cm1): 3254, 1643, 1568, 1466, 1405, 1378, 1293, 1254,
1158, 1020, 844, 772, 743, 695, 646. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.03 (s, 1H, –NH), 8.22–8.08 (m, 3H,
Ar-H), 8.000–7.961 (d, 1H, C‚CH, J= 15.6 Hz), 7.67–7.56
(m, 5H, Ar-H), 7.433–7.394 (d, 1H, CH‚C, J= 15.6 Hz),
7.36–7.32 (m, 1H, Ar-H), 3.80 (s, 3H, N–CH3), 3.01–2.97 (m,
1H, –CH), 0.82–0.59 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 162.4, 143.3, 141.8, 137.9,Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimi
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122.0, 118.9, 111.7, 31.7, 23.4, 6.3. MS: m/z= 345.2
(M+H). Anal. Calcd. for C22H20N2O2: C, 76.72; H, 5.85; N,
8.13. Found: C, 76.69; H, 5.82; N, 8.10.
2.3.2. N-cyclopropyl-3-(3-(4-fluorophenyl)-3-oxoprop-1-enyl)-
1-methyl-1H-indole-2-carboxamide (9b)
Yield: 0.18 g, 90%. Pale yellow solid, m.p. 200–201 C. IR
(neat, cm1): 3252, 1640, 1574, 1539, 1466, 1407, 1379, 1287,
1222, 1157, 1017, 834, 743. 1H NMR (DMSO-d6, 400 MHz,
d in ppm): 9.04 (s, 1H, –NH), 8.22–8.09 (m, 3H, Ar-H),
8.028–7.989 (d, 1H, C‚CH, J= 15.6 Hz), 7.63–7.51 (m, 5H,
Ar–H), 7.430–7.391 (d, 1H, CH‚C, J= 15.6 Hz), 3.78 (s,
3H, N–CH3), 3.01–2.92 (m, 1H, –CH), 0.84–0.59 (m, 4H, ali-
phatic). 13C NMR (DMSO-d6, 100 MHz, d ppm): 189.8,
169.6, 162.4, 143.5, 141.7, 135.7, 133.9, 133.8, 129.9, 128.6,
127.6, 122.8, 122.0, 120.2, 118.9, 117.4, 117.2, 111.7, 31.7,
23.4, 6.3. MS: m/z= 363.2 (M+H). Anal. Calcd. for C22H19-
FN2O2: C, 72.91; H, 5.28; N, 7.73. Found: C, 72.88; H, 5.26;
N, 7.70.
2.3.3. 3-(3-(4-Chlorophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (9c)
Yield: 0.17 g, 85%. Yellow solid, m.p. 232–233 C. IR (neat,
cm1): 3249, 1652, 1572, 1539, 1462, 1428, 1390, 1374, 1279,
1220, 1034, 828, 785, 746, 694. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.02 (s, 1H, –NH), 8.19–8.07 (m, 3H,
Ar-H), 7.972–7.933 (d, 1H, C‚CH, J= 15.6 Hz), 7.67–7.44
(m, 5H, Ar-H), 7.410–7.371 (d, 1H, CH‚C, J = 15.6 Hz),
3.78 (s, 3H, N–CH3), 3.00–2.98 (m, 1H, –CH), 0.84–0.59 (m,
4H, aliphatic). 13C NMR (DMSO-d6, 100 MHz, d ppm):
189.8, 162.4, 144.5, 143.7, 140.7, 135.8, 131.9, 131.4, 129.9,
128.6, 128.5, 128.4, 127.6, 122.8, 120.2, 119.6, 118.1, 111.7,
31.7, 23.4, 6.3. MS: m/z= 379.6 (M+H). Anal. Calcd. for
C22H19ClN2O2: C, 69.75; H, 5.05; N, 7.39. Found: C, 69.72;
H, 5.03; N, 7.36.
2.3.4. 3-(3-(4-Bromophenyl)-3-oxoprop-1-enyl)-N-cyclopropyl-
1-methyl-1H-indole-2-carboxamide (9d)
Yield: 0.16 g, 80%. Pale brown solid, m.p. 207–208 C. IR
(neat, cm1): 3247, 1672, 1644, 1577, 1552, 1511, 1439, 1288,
1249, 1174, 1105, 934, 850, 811, 793, 728, 645. 1H NMR
(DMSO-d6, 400 MHz, d in ppm): 9.05 (s, 1H, –NH), 8.19–
8.07 (m, 3H, Ar-H), 7.963–7.924 (d, 1H, C‚CH,
J= 15.6 Hz), 7.61–7.47 (m, 5H, Ar-H), 7.410–7.371 (d, 1H,
CH‚C, J= 15.6 Hz), 3.77 (s, 3H, N–CH3), 3.00–2.97 (m,
1H, –CH), 0.84–0.59 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 162.4, 144.5, 143.7, 135.8,
132.7, 132.1, 131.9, 131.7, 129.8, 129.0, 128.6, 127.6, 122.8,
120.2, 119.6, 118.1, 111.7, 31.7, 23.4, 6.3. MS: m/z= 424.1
(M+H). Anal. Calcd. for C22H19BrN2O2: C, 62.42; H, 4.52;
N, 6.62. Found: C, 62.39; H, 4.50; N, 6.59.
2.3.5. N-cyclopropyl-3-(3-(4-methoxyphenyl)-3-oxoprop-1-
enyl)-1-methyl-1H-indole-2-carboxamide (9e)
Yield: 0.18 g, 90%. White solid, m.p. 185–186 C. IR (neat,
cm1): 3399, 1655, 1638, 1579, 1554, 1511, 1438, 1294, 1253,
1222, 1111, 836, 818, 735, 701, 652. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.01 (s, 1H, –NH), 8.22–8.10 (m, 3H,dine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Synthesis and evaluation of indole-pyrimidine hybrids 5Ar-H), 7.97–7.931 (d, 1H, C‚CH, J= 15.6 Hz), 7.683–7.644
(d, 1H, CH‚C, J= 15.6 Hz), 7.62–7.02 (m, 5H, Ar-H), 3.86
(s, 3H, O–CH3), 3.78 (s, 3H, N–CH3), 3.00–2.98 (m, 1H,
–CH), 0.80–0.61 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d ppm): 189.8, 165.7, 162.5, 144.2, 143.6, 131.1,
130.5, 130.32, 128.8, 128.6, 127.5, 122.8, 120.4, 119.6, 118.1,
115.3, 114.8, 111.7, 54.4, 31.7, 23.4, 6.4. MS: m/z= 375.4
(M+H). Anal. Calcd. for C23H22N2O3: C, 73.78; H, 5.92; N,
7.48. Found: C, 7.75; H, 5.90; N, 7.45.
2.3.6. N-cyclopropyl-1-methyl-3-(3-oxo-3-p-tolylprop-1-enyl)-
1H-indole-2-carboxamide (9f)
Yield: 0.18 g, 91%. Pale yellow solid, m.p. 174–175 C. IR
(neat, cm1): 3248, 1638, 1572, 1518, 1460, 1404, 1377,
1287, 1221, 1109, 1020, 823, 742. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.02 (s, 1H, –NH), 8.21–8.00 (m,
3H, Ar-H), 7.985–7.946 (d, 1H, C‚CH, J= 15.6 Hz),
7.66–7.37 (m, 5H, Ar-H), 7.363–7.324 (d, 1H, CH‚C,
J = 15.6 Hz), 3.79 (s, 3H, N–CH3), 3.01–2.97 (m, 1H,
–CH), 2.41 (s, 3H, –CH3), 0.82–0.59 (m, 4H, aliphatic).
13C NMR (DMSO-d6, 100 MHz, d ppm): 189.8, 162.5,
144.3, 144.2, 143.6, 133.9, 129.8, 129.3, 129.1, 128.8,
128.6, 127.5, 122.8, 120.4, 119.6, 118.1, 111.7, 31.7, 23.4,
21.5, 6.4. MS: m/z= 359.2 (M+H). Anal. Calcd. for
C23H22N2O2: C, 77.07; H, 6.19; N, 7.82. Found: C, 77.04;
H, 6.16; N, 7.79.
2.3.7. N-cyclopropyl-3-(3-(3-fluorophenyl)-3-oxoprop-1-enyl)-
1-methyl-1H-indole-2-carboxamide (9g)
Yield: 0.17 g, 85%. Yellow solid, m.p. 211–212 C. IR (neat,
cm1): 3253, 1643, 1575, 1543, 1466, 1409, 1379, 1288, 1230,
1157, 1018, 834, 745. 1H NMR (DMSO-d6, 400 MHz, d in
ppm): 9.04 (s, 1H, –NH), 8.14–7.97 (m, 3H, Ar–H),
7.969–7.930 (d, 1H, C‚CH, J= 15.6 Hz), 7.87–7.72 (m, 5H,
Ar–H), 7.660–7.699 (d, 1H, CH‚C, J= 15.6 Hz), 3.78
(s, 3H, N–CH3), 3.01–2.94 (m, 1H, –CH), 0.83–0.59 (m, 4H,
aliphatic). 13C NMR (DMSO-d6, 100 MHz, d ppm): 189.8,
163.5, 162.4, 144.6, 143.6, 139.3, 131.3, 129.9, 128.6, 127.6,
125.2, 122.8, 122.0, 120.2, 119.1, 118.6, 115.4, 111.7, 31.7,
23.4, 6.3. MS: m/z= 363.2 (M+H). Anal. Calcd. for
C22H19FN2O2: C, 72.91; H, 5.28; N, 7.73. Found: C, 72.88;
H, 5.26; N, 7.70.
2.3.8. 3-(3-(3-Chlorophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (9h)
Yield: 0.17 g, 86%. White solid, m.p. 203–204 C. IR (neat,
cm1): 3248, 1659, 1560, 1536, 1461, 1431, 1392, 1374, 1278,
1220, 1035, 829, 785, 744, 696. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.04 (s, 1H, –NH), 8.24–8.09 (m, 3H,
Ar–H), 7.984–7.945 (d, 1H, C‚CH, J= 15.6 Hz), 7.80–7.53
(m, 5H, Ar–H), 7.463–7.424 (d, 1H, CH‚C, J= 15.6 Hz),
3.78 (s, 3H, N–CH3), 3.00–2.98 (m, 1H, –CH), 0.83–0.57 (m,
4H, aliphatic). 13C NMR (DMSO-d6, 100 MHz, d ppm):
189.8, 162.4, 144.5, 143.7, 139.1, 136.0, 134.5, 130.9, 130.1,
129.9, 128.7, 128.4, 127.6, 122.8, 120.2, 119.6, 118.1, 111.7,
31.7, 23.4, 6.3. MS: m/z= 379.6 (M+H). Anal. Calcd. for
C22H19ClN2O2: C, 69.75; H, 5.05; N, 7.39. Found: C, 69.72;
H, 5.03; N, 7.36.Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.0032.3.9. 3-(3-(3-Bromophenyl)-3-oxoprop-1-enyl)-N-cyclopropyl-
1-methyl-1H-indole-2-carboxamide (9i)
Yield: 0.16 g, 81%. Pale yellow solid, m.p. 196–197 C. IR
(neat, cm1): 3249, 1670, 1651, 1577, 1552, 1513, 1439, 1274,
1249, 1174, 1105, 938, 850, 811, 793, 728, 647. 1H NMR
(DMSO-d6, 400 MHz, d in ppm): 9.03 (s, 1H, –NH), 8.19–
8.07 (m, 3H, Ar-H), 7.971–7.932 (d, 1H, C‚CH,
J= 15.6 Hz), 7.56–7.42 (m, 5H, Ar-H), 7.396–7.357 (d, 1H,
CH‚C, J= 15.6 Hz), 3.77 (s, 3H, N–CH3), 3.00–2.97 (m,
1H, –CH), 0.84–0.59 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 162.4, 144.5, 143.7, 141.3,
137.1, 133.4, 131.9, 129.8, 129.0, 128.6, 127.6, 125.0, 122.8,
120.2, 119.7, 118.1, 111.7, 31.7, 23.4, 6.3. MS: m/z= 424.4
(M+H). Anal. Calcd. for C22H19BrN2O2: C, 62.42; H, 4.52;
N, 6.62. Found: C, 62.39; H, 4.50; N, 6.59.
2.3.10. N-cyclopropyl-3-(3-(3-methoxyphenyl)-3-oxoprop-1-
enyl)-1-methyl-1H-indole-2-carboxamide (9j)
Yield: 0.16 g, 80%. Pale yellow solid, m.p. 190–191 C. IR
(neat, cm1): 3397, 1655, 1640, 1581, 1555, 1511, 1439, 1286,
1250, 1222, 1111, 836, 818, 735, 705, 653. 1H NMR (DMSO-
d6, 400 MHz, d in ppm): 9.01 (s, 1H, –NH), 7.97–7.931 (d,
1H, C‚CH, J= 15.6 Hz), 7.682–7.643 (d, 1H, CH‚C,
J= 15.6 Hz), 3.87 (s, 3H, O–CH3), 3.78 (s, 3H, N–CH3),
3.02–2.97 (m, 1H, –CH), 0.80–0.61 (m, 4H, aliphatic). 13C
NMR (DMSO-d6, 100 MHz, d ppm): 189.8, 163.7, 162.5,
144.2, 143.6, 138.2, 130.5, 129.7, 128.8, 127.5, 125.3, 121.3,
122.8, 120.2, 119.7, 118.1, 115.3, 111.7, 54.4, 31.7, 23.4, 6.4.
MS: m/z= 375.4 (M+H). Anal. Calcd. for C23H22N2O3: C,
73.78; H, 5.92; N, 7.48. Found: C, 73.75; H, 5.90; N, 7.45.
2.3.11. N-cyclopropyl-1-methyl-3-(3-oxo-3-m-tolylprop-1-
enyl)-1H-indole-2-carboxamide (9k)
Yield: 0.17 g, 85%. Yellow solid, m.p. 189–190 C. IR (neat,
cm1): 3248, 1638, 1573, 1520, 1461, 1405, 1377, 1287, 1221,
1109, 1021, 825, 745. 1H NMR (DMSO-d6, 400 MHz, d in
ppm): 9.03 (s, 1H, –NH), 8.36–8.17 (m, 3H, Ar-H),
7.974–7.935 (d, 1H, C‚CH, J= 15.6 Hz), 7.77–7.54 (m, 5H,
Ar-H), 7.447–7.408 (d, 1H, CH‚C, J = 15.6 Hz), 3.79
(s, 3H, N–CH3), 3.01–2.97 (m, 1H, –CH), 2.43 (s, 3H,
–CH3), 0.81–0.59 (m, 4H, aliphatic).
13C NMR (DMSO-d6,
100 MHz, d ppm): 189.8, 162.5, 140.7, 138.8, 138.6, 137.9,
137.6, 133.7, 129.1, 129.0, 125.9, 124.6, 124.5, 122.8, 122.0,
118.0, 111.7, 110.9, 31.7, 23.4, 21.5, 6.4. MS: m/z= 359.2
(M+H). Anal. Calcd. for C23H22N2O2: C, 77.07; H, 6.19; N,
7.82. Found: C, 77.04; H, 6.16; N, 7.80.
2.3.12. N-cyclopropyl-5-fluoro-1-methyl-3-(3-oxo-3-
phenylprop-1-enyl)-1H-indole-2-carboxamide (9l)
Yield: 0.19 g, 94%. White solid, m.p. 196–197 C. IR (neat,
cm1): 3251, 1641, 1571, 1540, 1484, 1459, 1383, 1279, 1173,
1130, 846, 797, 771, 695, 646. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.04 (s, 1H, –NH), 8.12–8.00 (m, 3H,
Ar-H), 7.941–7.902 (d, 1H, C‚CH, J= 15.6 Hz), 7.68–7.62
(m, 3H, Ar-H), 7.604–7.565 (d, 1H, CH‚C, J= 15.6 Hz),
7.55–7.22 (m, 2H, Ar-H), 3.78 (s, 3H, N–CH3), 2.98–2.95 (m,
1H, –CH), 0.80–0.57 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 162.4, 158.7, 144.3, 140.5,ine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
6 N. Gokhale et al.139.1, 135.6, 130.4, 129.9, 129.4, 128.7, 128.6, 128.1, 127.5,
118.7, 113.3, 112.8, 112.7, 31.7, 23.4, 6.3. MS: m/z= 363.4
(M+H). Anal. Calcd. for C22H19FN2O2: C, 72.91; H, 5.28;
N, 7.73. Found: C, 72.89; H, 5.25; N, 7.71.
2.3.13. N-cyclopropyl-5-fluoro-3-(3-(4-fluorophenyl)-3-
oxoprop-1-enyl)-1-methyl-1H-indole-2-carboxamide (9m)
Yield: 0.18 g, 91%. Orange solid, m.p. 207–208 C. IR (neat,
cm1): 3254, 1642, 1575, 1541, 1509, 1485, 1406, 1383, 1277,
1159, 1131, 1019, 835, 794, 643. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.04 (s, 1H, –NH), 8.25–8.03 (m, 3H,
Ar-H), 7.947–7.908 (d, 1H, C‚CH, J= 15.6 Hz), 7.68–7.65
(m, 1H, Ar-H), 7.607–7.568 (d, 1H, CH‚C, J= 15.6 Hz),
7.38–7.22 (m, 3H, Ar-H), 3.78 (s, 3H, N–CH3), 2.99–2.94 (m,
1H, –CH), 0.84–0.57 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.7, 169.6, 162.4, 158.8, 144.6,
140.3, 135.6, 133.7, 133.2, 130.7, 128.6, 127.6, 118.9, 117.2,
117.2, 113.3, 112.8, 112.7, 31.7, 23.4, 6.3. MS: m/z= 381.2
(M+H). Anal. Calcd. for C22H18F2N2O2: C, 69.46; H, 4.77;
N, 7.36. Found: C, 69.44; H, 4.75; N, 7.34.
2.3.14. 3-(3-(4-Chlorophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (9n)
Yield: 0.17 g, 85%. Yellow solid, m.p. 235–236 C. IR (neat,
cm1): 3252, 1571, 1540, 1483, 1409, 1284, 1242, 1222, 1171,
1132, 1024, 847, 791, 667. 1H NMR (DMSO-d6, 400 MHz, d
in ppm): 9.03 (s, 1H, –NH), 8.32–8.11 (m, 3H, Ar-H), 7.927–
7.888 (d, 1H, C‚CH, J= 15.6 Hz), 7.73–7.65 (m, 1H,
Ar-H), 7.558–7.519 (d, 1H, CH‚C, J= 15.6 Hz), 7.40–7.19
(m, 3H, Ar-H), 3.78 (s, 3H, N–CH3), 3.00–2.95 (m, 1H,
–CH), 0.83–0.56 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d ppm): 189.8, 162.4, 158.8, 144.5, 143.7, 140.7,
135.8, 132.3, 131.9, 131.4, 128.6, 128.5, 128.4, 127.6, 119.6,
113.3, 112.8, 112.3, 31.7, 23.4, 6.3. MS: m/z= 397.4
(M+H). Anal. Calcd. for C22H18ClFN2O2: C, 66.58;
H, 4.57; N, 7.06. Found: C, 66.55; H, 4.54; N, 7.03.
2.3.15. 3-(3-(4-Bromophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (9o)
Yield: 0.16 g, 81%. Pale yellow solid, m.p. 240–241 C. IR
(neat, cm1): 3253, 1655, 1635, 1589, 1531, 1477, 1369, 1294,
1276, 1247, 1175, 1106, 930, 838, 815, 797, 727, 667. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 9.03 (s, 1H, –NH),
8.32–8.11 (m, 3H, Ar-H), 7.869–7.830 (d, 1H, C‚CH,
J= 15.6 Hz), 7.70–7.61 (m, 1H, Ar-H), 7.571–7.532 (d, 1H,
CH‚C, J= 15.6 Hz), 7.31–7.13 (m, 3H, Ar-H), 3.78 (s, 3H,
N–CH3), 3.00–2.94 (m, 1H, –CH), 0.83–0.57 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d ppm): 189.8, 162.4,
158.8, 144.5, 140.6, 135.8, 132.7, 132.1, 131.9, 131.7, 130.3,
129.0, 128.6, 127.6, 119.6, 113.3, 112.8, 112.3, 31.7, 23.4, 6.3.
MS: m/z= 442.3 (M+H). Anal. Calcd. for C22H18BrFN2O2:
C, 59.88; H, 4.11; N, 6.35. Found: C, 59.85; H, 4.08; N, 6.32.
2.3.16. N-cyclopropyl-5-fluoro-3-(3-(4-methoxyphenyl)-3-
oxoprop-1-enyl)-1-methyl-1H-indole-2-carboxamide (9p)
Yield: 0.19 g, 93%. Pale yellow solid, m.p. 221–222 C. IR
(neat, cm1): 3243, 1658, 1640, 1582, 1557, 1479, 1371, 1298,
1277, 1257, 1225, 1175, 1111, 932, 837, 817, 798, 695. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 9.03 (s, 1H, –NH),Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimi
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.0038.17–7.94 (m, 3H, Ar-H), 7.932–7.893 (d, 1H, C‚CH,
J= 15.6 Hz), 7.69–7.66 (m, 1H, Ar-H), 7.628–7.589
(d, 1H, CH‚C, J= 15.6 Hz), 7.29–7.07 (m, 3H, Ar-H), 3.87
(s, 3H, O–CH3), 3.79 (s, 3H, N–CH3), 3.01–2.97 (m, 1H,
–CH), 0.82–0.60 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d ppm): 189.7, 165.7, 162.5, 157.8, 144.2, 140.6,
131.8, 131.1, 130.5, 130.3, 128.8, 127.5, 118.4, 115.3, 114.8,
113.3, 112.8, 112.3, 54.4, 31.7, 23.4, 6.4. MS: m/z= 393.4
(M+H). Anal. Calcd. for C23H21FN2O3: C, 70.40; H, 5.39;
N, 7.14. Found: C, 70.38; H, 5.35; N, 7.11.
2.3.17. N-cyclopropyl-5-fluoro-1-methyl-3-(3-oxo-3-p-
tolylprop-1-enyl)-1H-indole-2-carboxamide (9q)
Yield: 0.18 g, 90%. Yellow solid, m.p. 199–200 C. IR (neat,
cm1): 3247, 1639, 1571, 1541, 1487, 1407, 1386, 1282, 1246,
1220, 1166, 1130, 789, 646. 1H NMR (DMSO-d6, 400 MHz,
d in ppm): 9.03 (s, 1H, –NH), 8.04–7.99 (m, 3H, Ar-H),
7.928–7.889 (d, 1H, C‚CH, J= 15.6 Hz), 7.68–7.64 (m, 1H,
Ar-H), 7.593–7.554 (d, 1H, CH‚C, J= 15.6 Hz), 7.36–7.22
(m, 3H, Ar-H), 3.77 (s, 3H, N–CH3), 2.99–2.95 (m, 1H,
–CH), 2.39 (s, 3H, –CH3), 0.80–0.57 (m, 4H, aliphatic).
13C NMR (DMSO-d6, 100 MHz, d ppm): 189.7, 162.5,
157.8, 144.3, 144.2, 140.6, 133.9, 130.7, 129.3, 129.1, 128.8,
128.6, 127.5, 118.4, 113.3, 112.8, 112.3, 31.7, 23.4, 21.5,
6.4. MS: m/z= 377.6 (M+H). Anal. Calcd. for C23H21FN2O2:
C, 73.39; H, 5.62; N, 7.44. Found: C, 73.36; H, 5.60;
N, 7.41.
2.3.18. N-cyclopropyl-5-fluoro-3-(3-(3-fluorophenyl)-3-
oxoprop-1-enyl)-1-methyl-1H-indole-2-carboxamide (9r)
Yield: 0.17 g, 86%. White solid, m.p. 210–211 C. IR (neat,
cm1): 3255, 1642, 1575, 1541, 1509, 1486, 1406, 1381, 1277,
1160, 1131, 1019, 836, 794, 645. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.04 (s, 1H, –NH), 8.30–8.10 (m, 3H,
Ar-H), 7.988–7.949 (d, 1H, C‚CH, J= 15.6 Hz), 7.82–7.89
(m, 1H, Ar-H), 7.682–7.643 (d, 1H, CH‚C, J= 15.6 Hz),
7.50–7.31 (m, 3H, Ar-H), 3.78 (s, 3H, N–CH3), 2.99–2.94 (m,
1H, –CH), 0.84–0.57 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 163.5, 162.4, 158.8, 144.6,
140.3, 139.3, 131.3, 130.2, 128.6, 127.6, 125.2, 122.0, 118.7,
115.4, 113.3, 112.8, 112.7, 31.7, 23.4, 6.3. MS: m/z= 381.2
(M+H). Anal. Calcd. for C22H18F2N2O2: C, 69.46; H, 4.77;
N, 7.36. Found: C, 69.44; H, 4.75; N, 7.34.
2.3.19. 3-(3-(3-Chlorophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (9s)
Yield: 0.18 g, 91%. Pale yellow solid, m.p. 233–234 C. IR
(neat, cm1): 3253, 1574, 1540, 1484, 1410, 1284, 1244, 1223,
1171, 1132, 1024, 847, 794, 667. 1H NMR (DMSO-d6,
400 MHz, d in ppm): 9.03 (s, 1H, –NH), 8.49–8.31 (m, 3H,
Ar-H), 7.940–7.901 (d, 1H, C‚CH, J= 15.6 Hz), 7.87–7.78
(m, 1H, Ar-H), 7.610–7.571 (d, 1H, CH‚C, J= 15.6 Hz),
7.53–7.28 (m, 3H, Ar-H), 3.78 (s, 3H, N–CH3), 3.00–2.95 (m,
1H, –CH), 0.83–0.56 (m, 4H, aliphatic). 13C NMR (DMSO-
d6, 100 MHz, d ppm): 189.8, 162.4, 157.8, 144.5, 143.6,
139.1, 136.0, 134.5, 132.3, 130.9, 130.1, 128.7, 128.4, 127.6,
119.6, 113.3, 112.8, 112.3, 31.7, 23.4, 6.3. MS: m/z= 397.4
(M+H). Anal. Calcd. for C22H18ClFN2O2: C, 66.58; H,
4.57; N, 7.06. Found: C, 66.55; H, 4.54; N, 7.03.dine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Synthesis and evaluation of indole-pyrimidine hybrids 72.3.20. 3-(3-(3-Bromophenyl)-3-oxoprop-1-enyl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (9t)
Yield: 0.17 g, 85%. Pale brown solid, m.p. 235–236 C. IR
(neat, cm1): 3261, 1653, 1649, 1589, 1530, 1477, 1369, 1294,
1266, 1247, 1179, 1102, 934, 837, 815, 797, 725, 668. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 9.03 (s, 1H, –NH),
8.41–8.15 (m, 3H, Ar-H), 7.822–7.783 (d, 1H, C‚CH,
J= 15.6 Hz), 7.76–7.69 (m, 1H, Ar-H), 7.555–7.516 (d, 1H,
CH‚C, J= 15.6 Hz), 7.43–7.06 (m, 3H, Ar-H), 3.78 (s, 3H,
N–CH3), 3.00–2.94 (m, –1H, –CH), 0.84–0.57 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d ppm): 189.8, 162.4,
157.8, 144.5, 141.3, 140.1, 137.2, 133.4, 131.9, 130.3, 129.0,
128.6, 127.6, 124.6, 119.6, 113.3, 112.8, 112.3, 31.7, 23.4, 6.3.
MS: m/z= 442.3 (M+H). Anal. Calcd. for C22H18BrFN2O2:
C, 59.88; H, 4.11; N, 6.35. Found: C, 59.85; H, 4.08; N, 6.32.
2.3.21. N-cyclopropyl-5-fluoro-3-(3-(3-methoxyphenyl)-3-
oxoprop-1-enyl)-1-methyl-1H-indole-2-carboxamide (9u)
Yield: 0.16 g, 80%. Pale yellow solid, m.p. 215–216 C. IR
(neat, cm1): 3246, 1660, 1633, 1582, 1558, 1482, 1371, 1298,
1275, 1257, 1224, 1175, 1112, 932, 837, 817, 798, 693. 1H
NMR (DMSO-d6, 400 MHz, d in ppm): 9.03 (s, 1H, –NH),
8.17–7.94 (m, 3H, Ar-H), 7.87–7.831 (d, 1H, C‚CH,
J= 15.6 Hz), 7.70–7.65 (m, 1H, Ar-H), 7.619–7.580 (d, 1H,
CH‚C, J= 15.6 Hz), 7.42–7.11(m, 3H, Ar-H), 3.87 (s, 3H,
O–CH3), 3.79 (s, 3H, N–CH3), 3.01–2.96 (m, 1H, –CH),
0.82–0.59 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d ppm): 189.8, 163.7, 162.5, 157.8, 144.2, 140.6,
138.2, 131.1, 130.5, 128.8, 127.5, 125.3, 121.3, 118.4, 115.3,
113.3, 112.8, 112.3, 54.4, 31.7, 23.4, 6.4. MS: m/z= 393.4
(M+H). Anal. Calcd. for C23H21FN2O3: C, 70.40; H, 5.39;
N, 7.14. Found: C, 70.38; H, 5.35; N, 7.11.
2.3.22. N-cyclopropyl-5-fluoro-1-methyl-3-(3-oxo-3-m-
tolylprop-1-enyl)-1H-indole-2-carboxamide (9v)
Yield: 0.17 g, 85%. Off-white solid, m.p. 220–221 C. IR (neat,
cm1): 3247, 1640, 1571, 1541, 1487, 1407, 1387, 1282, 1246,
1222, 1164, 1130, 787, 646. 1H NMR (DMSO-d6, 400 MHz,
d in ppm): 9.03 (s, 1H, –NH), 8.12–7.97 (m, 3H, Ar-H),
7.933–7.894 (d, 1H, C‚CH, J= 15.6 Hz), 7.72–7.66 (m, 1H,
Ar-H), 7.585–7.546 (d, 1H, CH‚C, J= 15.6 Hz), 7.36–7.21
(m, 3H, Ar-H), 3.77 (s, 3H, N–CH3), 2.99–2.95 (m, 1H,
–CH), 2.38 (s, 3H, –CH3), 0.80–0.58 (m, 4H, aliphatic).
13C
NMR (DMSO-d6, 100 MHz, d ppm): 189.8, 162.5, 158.1,
140.7, 138.8, 138.6, 137.9, 137.6, 133.7, 129.1, 129.0, 127.9,
125.1, 119.0, 113.5, 112.5, 112.3, 31.7, 23.4, 21.5, 6.4. MS:
m/z= 377.6 (M+H). Anal. Calcd. for C23H21FN2O2: C,
73.39; H, 5.62; N, 7.44. Found: C, 73.36; H, 5.60; N, 7.41.
2.3.23. General procedure for the synthesis of target compounds
(10a–v)
A mixture comprising of the scaffold 9a–v (0.15 g) and guani-
dine hydrochloride (2 equivalents) in ethanol was taken in a
dry round bottom ﬂask to which ethanolic NaOH was added
with stirring at 0 C. The reaction mass was reﬂuxed for 12 h
at 80 C. Completion of the reaction was determined using
TLC and after complete consumption of the starting material,
the reaction mass was kept for cooling. It was then poured into
crushed ice with stirring and ﬁltered in the cold condition. The
obtained solid was washed with cold water, dried properly andPlease cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.003recrystallized using ethanol to afford the pure target com-
pounds 10a–v.
2.4. The structural characterization of the final compounds is
listed below
2.4.1. 3-(2-Amino-6-phenylpyrimidin-4-yl)-N-cyclopropyl-1-
methyl-1H-indole-2-carboxamide (10a)
IR (neat, cm1): 3203, 2978, 1636, 1568, 1464, 1405, 1378,
1285, 1220, 1158, 1020, 844, 772, 743, 695, 645. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.16 (s, 1H, –NH), 8.47–
7.21 (m, 10H, Ar-H), 6.67 (s, 2H, –NH2), 3.81 (s, 3H, N–
CH3), 3.01–2.99 (m, 1H, –CH), 0.73–0.48 (m, 4H, aliphatic).
13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3, 164.0,
163.9, 162.4, 143.7, 139.5, 136.3, 133.6, 130.7, 129.2, 128.4,
126.9, 126.0, 123.1, 121.6, 118.4, 115.2, 110.9, 102.5, 31.6,
23.4, 6.0. MS: m/z= 384.2 (M+H). Anal. Calcd. for
C23H21N5O: C, 72.04; H, 5.52; N, 18.26. Found: C, 71.99;
H, 5.48; N, 18.24.
2.4.2. 3-(2-Amino-6-(4-fluorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10b)
IR (neat, cm1): 3207, 2984, 1640, 1575, 1541, 1509, 1466,
1407, 1379, 1287, 1221, 1157, 1016, 834, 743. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.15 (s, 1H, –NH), 8.48–
7.05 (m, 9H, Ar-H), 6.69 (s, 2H, –NH2), 3.81 (s, 3H, N–
CH3), 3.00–2.96 (m, 1H, –CH), 0.70–0.46 (m, 4H, aliphatic).
13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3, 163.8,
163.9, 162.4, 162.0, 143.7, 139.5, 133.6, 130.4, 129.8, 128.4,
123.1, 121.6, 118.4, 117.6, 117.3, 115.2, 110.9, 102.5, 31.6,
23.4, 6.0. MS: m/z= 402.2 (M+H). Anal. Calcd. for C23H20-
FN5O: C, 68.81; H, 5.02; N, 17.45. Found: C, 68.77; H, 4.91;
N, 17.39.
2.4.3. 3-(2-Amino-6-(4-chlorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10c)
IR (neat, cm1): 3346, 3217, 1658, 1560, 1536, 1465, 1431,
1390, 1376, 1278, 1220, 1035, 829, 784, 744, 721, 696. 1H
NMR (400 MHz, DMSO-d6, d in ppm): 9.13 (s, 1H, –NH),
8.45–7.18 (m, 9H, Ar-H), 6.72 (s, 2H, –NH2), 3.80 (s, 3H,
N–CH3), 3.00–2.98 (m, 1H, –CH), 0.76–0.48 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.9, 164.0, 162.3, 143.9, 139.5, 135.4, 133.5, 132.5, 130.7,
129.2, 128.4, 127.1, 123.1, 121.6, 118.5, 115.3, 110.3, 102.5,
31.4, 23.4, 6.0. MS: m/z= 418.4 (M+H). Anal. Calcd. for
C23H20ClN5O: C, 66.10; H, 4.82; N, 16.76. Found: C, 66.04;
H, 4.77; N, 16.70.
2.4.4. 3-(2-Amino-6-(4-bromophenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10d)
IR (neat, cm1): 3328, 3202, 1578, 1564, 1538, 1486, 1465,
1393, 1285, 1222, 1160, 1135, 1106, 1009, 825, 795, 742, 663.
1H NMR (400 MHz, DMSO-d6, d in ppm): 9.11 (s, 1H,
–NH), 8.45–7.18 (m, 9H, Ar-H), 6.71 (s, 2H, –NH2), 3.80 (s,
3H, N–CH3), 3.02–2.98 (m, 1H, –CH), 0.72–0.46 (m, 4H, ali-
phatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.9, 163.9, 162.3, 143.7, 140.5, 135.5, 133.6, 132.3, 131.9,
129.6, 129.1, 124.7, 123.1, 121.6, 118.5, 115.3, 110.3, 102.5,
31.4, 23.4, 6.0. MS: m/z= 463.4 (M+H). Anal. Calcd. forine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
8 N. Gokhale et al.C23H20BrN5O: C, 59.75; H, 4.36; N, 15.15. Found: C, 59.71;
H, 4.29; N, 15.10.2.4.5. 3-(2-Amino-6-(4-methoxyphenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10e)
IR (neat, cm1): 3331, 3209, 3009, 1638, 1605, 1569, 1538,
1512, 1287, 1253, 1222, 1176, 1134, 1111, 1028, 832, 796,
743. 1H NMR (400 MHz, DMSO-d6, d in ppm): 9.18 (s, 1H,
–NH), 8.42–7.07 (m, 9H, Ar-H), 6.59 (s, 2H, –NH2), 3.83 (s,
3H, N–CH3), 3.81 (s, 3H, O–CH3), 3.01–2.94 (m, 1H, –CH),
0.75–0.48 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.3, 163.9, 163.7, 162.3, 160.2, 143.5,
140.6, 135.6, 127.8, 127.1, 125.4, 123.1, 121.6, 118.6, 115.3,
113.7, 113.2, 109.8, 102.7, 53.8, 31.4, 23.4, 6.0. MS:
m/z= 414.2 (M+H). Anal. Calcd. for C24H23N5O2: C,
69.72; H, 5.61; N, 16.94. Found: C, 69.66; H, 5.58; N, 16.89.2.4.6. 3-(2-Amino-6-p-tolylpyrimidin-4-yl)-N-cyclopropyl-1-
methyl-1H-indole-2-carboxamide (10f)
IR (neat, cm1): 3346, 3031, 1638, 1570, 1513, 1464, 1404,
1377, 1286, 1220, 1110, 1020, 820, 742. 1H NMR (400 MHz,
DMSO-d6, d in ppm): 9.17 (s, 1H, –NH), 8.43–7.10 (m, 9H,
Ar-H), 6.69 (s, 2H, –NH2), 3.83 (s, 3H, N–CH3), 3.00–2.97
(m, 1H, –CH), 2.38 (s, 3H, –CH3), 0.72–0.50 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.2,
163.9, 163.7, 162.2, 140.5, 139.7, 138.1, 135.2, 133.5, 129.8,
126.8, 125.94, 125.8, 123.1, 121.6, 118.4, 115.2, 110.9, 104.3,
31.3, 23.4, 21.4, 6.0. MS: m/z= 398.2 (M+H). Anal. Calcd.
for C24H23N5O: C, 72.52; H, 5.83; N, 17.62. Found: C,
72.48; H, 5.79; N, 17.60.2.4.7. 3-(2-Amino-6-(3-fluorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10g)
IR (neat, cm1): 3341, 3294, 1613, 1572, 1466, 1440, 1403,
1379, 1285, 1220, 1160, 1108, 1020, 877, 818, 789, 743, 702.
1H NMR (400 MHz, DMSO-d6, d in ppm): 9.15 (s, 1H,
–NH), 8.43–7.09 (m, 9H, Ar-H), 6.74 (s, 2H, –NH2), 3.81 (s,
3H, N–CH3), 3.00–2.96 (m, 1H, –CH), 0.70–0.46 (m, 4H, ali-
phatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
164.0, 163.9, 162.4, 162.0, 141.7, 139.5, 138.4, 133.8, 130.5,
122.8, 123.4, 123.1, 121.6, 118.4, 116.6, 116.2, 115.2, 110.9,
102.6, 31.6, 23.4, 6.0. MS: m/z= 402.2 (M+H). Anal. Calcd.
for C23H20FN5O: C, 68.81; H, 5.02; N, 17.45. Found: C, 68.77;
H, 4.92; N, 17.38.2.4.8. 3-(2-Amino-6-(3-chlorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10h)
IR (neat, cm1): 3357, 3288, 1658, 1611, 1568, 1530, 1465,
1431, 1394, 1376, 1278, 1219, 1035, 829, 785, 744, 721, 698.
1H NMR (400 MHz, DMSO-d6, d in ppm): 9.16 (s, 1H,
–NH), 8.48–7.18 (m, 9H, Ar-H), 6.78 (s, 2H, –NH2), 3.80 (s,
3H, N–CH3), 3.01–2.99 (m, 1H, –CH), 0.73–0.46 (m, 4H, ali-
phatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.6, 163.5, 161.8, 141.6, 140.2, 138.5, 135.6, 134.7, 131.1,
129.3, 127.3, 124.0, 123.1, 121.7, 118.3, 116.6, 111.1, 102.9,
31.6, 23.4, 6.0. MS: m/z= 418.4 (M+H). Anal. Calcd. for
C23H20ClN5O: C, 66.10; H, 4.82; N, 16.76. Found: C, 66.04;
H, 4.77; N, 16.71.Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimi
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cyclopropyl-1-methyl-1H-indole-2-carboxamide (10i)
IR (neat, cm1): 3343, 3206, 1579, 1564, 1530, 1465, 1393,
1285, 1222, 1160, 1070, 1009, 825, 795, 743, 663. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.14 (s, 1H, –NH),
8.45–7.11 (m, 9H, Ar-H), 6.77 (s, 2H, –NH2), 3.81 (s, 3H,
N–CH3), 3.00–2.98 (m, 1H, –CH), 0.74–0.46 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.9, 163.9, 162.4, 143.7, 140.5, 135.5, 135.0, 132.8, 131.4,
129.9, 127.5, 124.7, 123.1, 121.6, 118.4, 115.3, 109.3, 103.2,
31.4, 23.4, 6.0. MS: m/z= 463.2 (M+H). Anal. Calcd. for
C23H20BrN5O: C, 59.75; H, 4.36; N, 15.15. Found: C, 59.71;
H, 4.29; N, 15.09.
2.4.10. 3-(2-Amino-6-(3-methoxyphenyl)pyrimidin-4-yl)-N-
cyclopropyl-1-methyl-1H-indole-2-carboxamide (10j)
IR (neat, cm1): 3325, 3005, 1611, 1569, 1465, 1285, 1223,
1160, 1044, 967, 869, 842, 787, 743, 701. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.15 (s, 1H, –NH),
8.45–7.07 (m, 9H, Ar-H), 6.68 (s, 2H, –NH2), 3.83 (s, 3H,
N–CH3), 3.80 (s, 3H, O–CH3), 3.02–2.97 (m, 1H, –CH),
0.72–0.47 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.3, 163.9, 163.7, 162.3, 160.2, 143.5,
140.6, 135.6, 133.2, 130.4, 123.1, 121.6, 120.2, 118.6, 115.3,
114.9, 110.5, 109.8, 102.7, 53.9, 31.4, 23.5, 6.0. MS:
m/z= 414.2 (M+H). Anal. Calcd. for C24H23N5O2: C,
69.72; H, 5.61; N, 16.94. Found: C, 69.66; H, 5.57; N, 16.89.
2.4.11. 3-(2-Amino-6-m-tolylpyrimidin-4-yl)-N-cyclopropyl-1-
methyl-1H-indole-2-carboxamide (10k)
IR (neat, cm1): 3205, 3047, 1637, 1570, 1465, 1403, 1378,
1286, 1219, 1161, 1021, 967, 871, 790, 742, 703. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.18 (s, 1H, –NH),
8.47–7.18 (m, 9H, Ar-H), 6.66 (s, 2H, –NH2), 3.81 (s, 3H,
N–CH3), 3.00–2.98 (m, 1H, –CH), 2.40 (s, 3H, –CH3),
0.72–0.50 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.2, 164.1, 164.0, 162.9, 138.3, 138.1,
137.0, 136.3, 131.4, 129.1, 127.5, 125.5, 124.2, 123.8, 123.1,
121.6, 112.2, 110.9, 104.1, 31.4, 23.4, 21.6, 6.0. MS:
m/z= 398.2 (M+1). Anal. Calcd. for C24H23N5O: C, 72.52;
H, 5.83; N, 17.62. Found: C, 72.48; H, 5.79; N, 17.60.
2.4.12. 3-(2-Amino-6-phenylpyrimidin-4-yl)-N-cyclopropyl-5-
fluoro-1-methyl-1H-indole-2-carboxamide (10l)
IR (neat, cm1): 3210, 3187, 1630, 1570, 1540, 1484, 1455,
1382, 1278, 1173, 1130, 846, 796, 771, 695, 645. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.15 (s, 1H, –NH),
8.33–7.16 (m, 9H, Ar-H), 6.72 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.00–2.99 (m, 1H, –CH), 0.73–0.45 (m, 4H,
aliphatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
164.0, 163.9, 162.4, 159.8, 138.1, 133.6, 130.7, 129.2, 126.9,
126.0, 125.9, 112.3, 112.2, 112.0, 111.7, 111.7, 108.3, 108.1,
103.2, 31.6, 23.5, 5.9. MS: m/z= 402.0 (M+H). Anal. Calcd.
for C23H20FN5O: C, 68.81; H, 5.02; N, 17.45. Found: C, 68.77;
H, 4.90; N, 17.39.
2.4.13. 3-(2-Amino-6-(4-fluorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10m)
IR (neat, cm1): 3326, 3291, 1602, 1574, 1541, 1509, 1484,
1406, 1382, 1277, 1157, 1130, 1019, 835, 793. 1H NMRdine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Synthesis and evaluation of indole-pyrimidine hybrids 9(400 MHz, DMSO-d6, d in ppm): 9.15 (s, 1H, –NH), 8.32–7.13
(m, 8H, Ar-H), 6.73 (s, 2H, –NH2), 3.79 (s, 3H, N–CH3), 3.01–
2.98 (m, 1H, –CH), 0.73–0.44 (m, 4H, aliphatic). 13C NMR
(DMSO-d6, 100 MHz, d in ppm): 164.3, 164.0, 163.5, 162.4,
162.0, 159.9, 141.7, 139.5, 136.4, 130.7, 129.2, 128.4, 118.4,
117.6, 117.3, 113.6, 112.4, 110.1, 110.0, 102.5, 31.6, 23.4, 6.0.
MS: m/z= 420.2 (M+H). Anal. Calcd. for C23H19F2N5O:
C, 65.86; H, 4.57; N, 16.70. Found: C, 65.80; H, 4.52; N, 16.64.
2.4.14. 3-(2-Amino-6-(4-chlorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10n)
IR (neat, cm1): 3218, 3117, 1571, 1540, 1483, 1408, 1280,
1241, 1222, 1171, 1132, 1023, 845, 791, 667. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.14 (s, 1H, –NH),
8.32–7.14 (m, 8H, Ar–H), 6.76 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.00–2.97 (m, 1H, –CH), 0.74–0.44 (m, 4H,
aliphatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.9, 163.5, 162.3, 159.7, 141.5, 140.2, 135.4, 133.5, 132.5,
130.7, 129.2, 128.4, 127.1, 118.2, 113.6, 112.4, 110.1, 102.5,
31.4, 23.4, 6.0. MS: m/z= 436.0 (M+H). Anal. Calcd. for
C23H19ClFN5O: C, 63.38; H, 4.39; N, 16.07. Found: C,
63.33; H, 4.37; N, 16.03.
2.4.15. 3-(2-Amino-6-(4-bromophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10o)
IR (neat, cm1): 3334, 3286, 1629, 1577, 1535, 1483, 1399,
1283, 1242, 1130, 1071, 1008, 829, 795. 1H NMR (400 MHz,
DMSO-d6, d in ppm): 9.18 (s, 1H, –NH), 8.32–7.11 (m, 8H,
Ar-H), 6.79 (s, 2H, –NH2), 3.81 (s, 3H, N–CH3), 3.01–2.99
(m, 1H, –CH), 0.74–0.46 (m, 4H, aliphatic). 13C NMR
(DMSO-d6, 100 MHz, d in ppm): 164.3, 163.9, 163.9, 162.3,
159.8, 140.7, 139.1, 135.7, 133.6, 132.3, 131.9, 129.6, 129.1,
124.7, 118.2, 113.6, 112.4, 110.1, 102.5, 31.4, 23.4, 6.0. MS:
m/z= 481.2 (M+H). Anal. Calcd. for C23H19BrFN5O: C,
57.51; H, 3.99; N, 14.58. Found: C, 57.48; H, 3.91; N, 14.53.
2.4.16. 3-(2-Amino-6-(4-methoxyphenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10p)
IR (neat, cm1): 3211, 3195, 1638, 1570, 1541, 1484, 1408,
1284, 1251, 1222, 1181, 1130, 1046, 845, 789, 742. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.19 (s, 1H, –NH),
9.18–7.08 (m, 8H, Ar-H), 6.67 (s, 2H, –NH2), 3.83 (s, 3H,
O–CH3), 3.79 (s, 3H, N–CH3), 3.00–2.97 (m, 1H, –CH),
0.73–0.48 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.3, 163.9, 163.7, 162.3, 160.2, 159.8,
140.5, 138.8, 135.6, 127.8, 127.1, 125.4, 118.2, 113.7, 113.6,
113.2, 112.4, 111.4, 102.7, 53.8, 31.4, 23.4, 6.0. MS:
m/z= 432.2 (M+H). Anal. Calcd. for C24H22FN5O2: C,
66.81; H, 5.14; N, 16.23. Found: C, 66.78; H, 5.09; N, 16.19.
2.4.17. 3-(2-Amino-6-p-tolylpyrimidin-4-yl)-N-cyclopropyl-5-
fluoro-1-methyl-1H-indole-2-carboxamide (10q)
IR (neat, cm1): 3327, 3214, 1636, 1571, 1542, 1487, 1406,
1386, 1282, 1246, 1220, 1166, 1131, 789. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.16 (s, 1H, –NH),
8.32–7.13 (m, 8H, Ar-H), 6.67 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.01–2.99 (m, 1H, –CH), 2.38 (s, 3H, –CH3),
0.74–0.46 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.2, 163.9, 163.7, 162.2, 159.7, 157.4,
140.5, 138.1, 135.2, 133.5, 129.8, 126.8, 125.9, 125.8, 112.2,Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.003112.2, 111.9, 111.7, 108.3, 102.8, 31.5, 23.4, 21.4, 5.9. MS:
m/z= 416.1 (M+H). Anal. Calcd. for C24H22FN5O: C,
69.38; H, 5.34; N, 16.86. Found; C, 69.33; H, 5.30; N, 16.82.
2.4.18. 3-(2-Amino-6-(3-fluorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10r)
IR (neat, cm1): 3215, 3119, 1624, 1572, 1485, 1406, 1335,
1281, 1248, 1220, 1192, 1130, 1023, 932, 882, 845, 749, 669.
1H NMR (400 MHz, DMSO-d6, d in ppm): 9.13 (s, 1H,
–NH), 8.30–7.13 (m, 8H, Ar-H), 6.77 (s, 2H, –NH2), 3.77
(s, 3H, N–CH3), 3.02-2.98 (m, 1H, –CH), 0.70–0.46 (m, 4H,
aliphatic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
164.0, 163.5, 162.4, 162.0, 159.9, 141.7, 139.5, 136.4, 133.8,
130.5, 122.8, 118.40 116.6, 116.2, 113.6, 110.1, 109.9, 103.1,
31.6, 23.4, 6.0. MS: m/z= 420.2 (M+H). Anal. Calcd. for
C23H19F2N5O: C, 65.86; H, 4.57; N, 16.70. Found: C, 65.80;
H, 4.52; N, 16.64.
2.4.19. 3-(2-Amino-6-(3-chlorophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10s)
IR (neat, cm1): 3209, 3125, 1567, 1539, 1483, 1405, 1280,
1242, 1222, 1174, 1130, 1023, 845, 789, 667. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.17 (s, 1H, –NH),
8.34–7.15 (m, 8H, Ar–H), 6.79 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.03–3.00 (m, 1H, –CH), 0.75–0.46 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.6, 163.5, 161.9, 159.8, 141.6, 140.2, 136.0, 135.6, 134.7,
131.1, 129.3, 127.3, 124.0, 116.3, 113.7, 113.1, 110.0, 102.9,
31.5, 23.5, 6.0. MS: m/z= 436.2 (M+H). Anal. Calcd. for
C23H19ClFN5O: C, 63.38; H, 4.39; N, 16.07. Found: C,
63.33; H, 4.37; N, 16.03.
2.4.20. 3-(2-Amino-6-(3-bromophenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10t)
IR (neat, cm1): 3213, 3186, 1623, 1574, 1538, 1482, 1404,
1279, 1242, 1222, 1172, 1130, 1069, 844, 787, 667. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.18 (s, 1H, –NH),
8.30–7.11 (m, 8H, Ar-H), 6.78 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.03–2.99 (m, 1H, –CH), 0.75–0.44 (m, 4H, alipha-
tic). 13C NMR (DMSO-d6, 100 MHz, d in ppm): 164.3,
163.9, 163.9, 162.4, 159.8, 141.8, 140.5, 135.5, 135.0, 132.8,
131.4, 129.9, 127.5, 124.7, 117.5, 113.4, 112.5, 109.6, 103.2,
31.4, 23.4, 6.0. MS: m/z= 481.2 (M+H). Anal. Calcd. for
C23H19BrFN5O: C, 57.51; H, 3.99; N, 14.58. Found: C,
57.47; H, 3.91; N, 14.53.
2.4.21. 3-(2-Amino-6-(3-methoxyphenyl)pyrimidin-4-yl)-N-
cyclopropyl-5-fluoro-1-methyl-1H-indole-2-carboxamide (10u)
IR (neat, cm1): 3208, 3191, 1633, 1570, 1541, 1484, 1406,
1284, 1251, 1224, 1176, 1130, 1044, 845, 789, 746. 1H
NMR (400 MHz, DMSO-d6, d in ppm): 9.16 (s, 1H,
–NH), 8.62–7.04 (m, 8H, Ar-H), 6.72 (s, 2H, –NH2), 3.84
(s, 3H, N–CH3), 3.78 (s, 3H, O–CH3), 3.02–2.98 (m, 1H,
–CH), 0.73–0.46 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.3, 163.9, 163.7, 162.3, 160.2,
159.9, 141.4, 139.9, 135.8, 133.3, 130.4, 120.2, 117.4, 114.9,
113.6, 112.5, 110.7, 109.1, 102.7, 53.9, 31.4, 23.5, 6.0. MS:
m/z= 432.2 (M+H). Anal. Calcd. for C24H22FN5O2: C,
66.81; H, 5.14; N, 16.23. Found: C, 66.78; H, 5.09;
N, 16.19.ine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
10 N. Gokhale et al.2.4.22. 3-(2-Amino-6-m-tolylpyrimidin-4-yl)-N-cyclopropyl-5-
fluoro-1-methyl-1H-indole-2-carboxamide (10v)
IR (neat, cm1): 3322, 3214, 1632, 1571, 1542, 1484, 1406,
1380, 1282, 1246, 1220, 1166, 1129, 789. 1H NMR
(400 MHz, DMSO-d6, d in ppm): 9.18 (s, 1H, –NH),
8.34–7.14 (m, 8H, Ar-H), 6.70 (s, 2H, –NH2), 3.79 (s, 3H,
N–CH3), 3.01–2.99 (m, 1H, –CH), 2.40 (s, 3H, –CH3),
0.75–0.50 (m, 4H, aliphatic). 13C NMR (DMSO-d6,
100 MHz, d in ppm): 164.2, 164.1, 164.0, 162.9, 159.8, 138.6,
138.1, 137.0, 134.2, 131.4, 129.1, 127.5, 125.5, 124.2, 117.4,
113.7, 112.2, 111.6, 104.1, 31.4, 23.4, 21.6, 6.0. MS:
m/z= 416.2 (M+H). Anal. Calcd. for C24H22FN5O: C,
69.38; H, 5.34; N, 16.86. Found; C, 69.33; H, 5.30; N, 16.82.
3. Pharmacology
3.1. Cell lines, chemicals and culture medium
HeLa (Human cervix carcinoma), HepG2 (Liver, Rhesus mon-
key) and MCF-7 (Human Breast carcinoma) cell lines were
procured from the National Centre for Cell Sciences
(NCCS), Pune, India. 3-(4,5-dimethyl thiazol-2-yl)-5-diphenyl
tetrazolium bromide (MTT), Foetal Bovine Serum (FBS),
Phosphate Buffered Saline (PBS), Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) and Trypsin were obtained from Sigma
Aldrich Co., St. Louis, USA, EDTA, glucose and antibiotics
from Hi-Media Laboratories Ltd., Mumbai and dimethyl sul-
foxide (DMSO) and propanol from Merck Ltd., Mumbai,
India. Stock cells were cultured in DMEM supplemented with
10% inactivated Foetal Bovine Serum (FBS), penicillin
(100 IU/mL), streptomycin (100 lg/mL) and amphotericin B
(5 lg/mL) in a humidiﬁed atmosphere of 5% CO2 at 37 C
until conﬂuent. The cells were dissociated with TPVG solution
(0.2% trypsin, 0.02% EDTA, 0.05% glucose in PBS). The
stock cultures were grown in 25 cm3 culture ﬂasks and all
experiments were carried out in 96 microtitre plates (Tarsons
India Pvt. Ltd., Kolkata, India).
3.2. In vitro cytotoxic activity
The monolayer cell culture was trypsinized and the cell count
was adjusted to 1.0  105 cells/mL using DMEM containing
10% FBS. To each well of the 96 well microtitre plate,
0.1 mL of the diluted cell suspension (approximately 10,000
cells) was added. After 24 h, when a partial monolayer was
formed, the supernatant was ﬂicked off, washed the monolayer
once with medium and 100 lL of different test concentrations
of test drugs were added on to the partial monolayer in
microtitre plates. The plates were then incubated at 37 C for
3 days in 5% CO2 atmosphere, and microscopic examination
was carried out and observations were noted every 24 h
interval. After 72 h, the drug solutions in the wells were
discarded and 50 lL of MTT in PBS was added to each well.
The plates were gently shaken and incubated for 3 h at 37 C
in 5% CO2 atmosphere. The supernatant was removed and
100 lL of propanol was added and the plates were gently
shaken to solubilize the formed formazan. The absorbance
was measured using a microplate reader at a wavelength of
540 nm. The percentage growth inhibition was calculated using
the following formula,Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimi
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 1003.3. Anti-microbial studies
The disc diffusion method for antimicrobial susceptibility test-
ing was carried out according to the standard method [33].
Nutrient agar (20 mL) was poured into each sterile Petri dish
after injecting cultures (100 lL) of microorganisms and med-
ium was distributed in the Petri dish homogeneously. Com-
pounds were ﬁltered with a pore size of 0.45 lm for
sterilization. All the compounds were dissolved in DMSO of
5 mg/mL. Empty sterilized discs of 6 mm (Schleicher and
Schuell, No. 2668, Germany) were impregnated with 10 lg of
compounds. The discs were placed on agar plates, and the
plates were incubated at 37 C for 24 h. The culture suspen-
sions were prepared and adjusted by comparing against 0.3
McFarland turbidity standard tubes. The inhibition zones
formed on the medium were evaluated in millimetre (mm).
The negative solvent control (DMSO) did not show any
antimicrobial activity. The studies were performed in triplicate
and the average reading was taken. The inhibition zones were
compared with those of reference disc, Ciproﬂoxacin for
antibacterial and Fluconazole for antifungal activity.
4. Results and discussion
4.1. Chemistry
The synthetic route of the intermediate and target compounds
is outlined in Scheme 1. The core indole-2-ester (4a/4b) moiety
was conveniently prepared using the Fischer-indole protocol
[34]. The indole-NH was then methylated using potassium car-
bonate (K2CO3) as base and tetra-n-butyl ammonium bromide
(n-TBAB) as phase transfer catalyst to give intermediates 5a
and 5b. The intermediates 6a/6b were synthesized by the
hydrolysis of the ester functional group in 5a/5b, using lithium
hydroxide (LiOH) as base in methanolic THF medium. The
obtained indole-2-acid was then coupled with cyclopropyl
amine using HATU (1-[Bis(dimethylamino)methylene]-1
H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexaﬂuoro phos-
phate) as the coupling agent and di-isopropylethyl amine
(DIPEA) as the base to give indole-2-amides 7a/7b in excellent
yields. In the next step, an aldehyde functionality was
introduced at position-3 of the indole ring by following the
Vilsmeier–Haack formylation process [35] to yield intermedi-
ates 8a/8b. The chalcones 9a–v were synthesized by
subjecting the formylated intermediates 8a/8b to conventional
base-catalysed Claisen–Schmidt condensation reaction with
acetophenone derivatives. Different acetophenones with
various substitutions at position-3 and position-4 of the phenyl
ring were employed to check their effect on biological activity.
The substitutions included electron withdrawing groups like
halogens and electron donating groups like methoxy and
methyl groups. These chalcones were then cyclized to
form indole-pyrimidine hybrids 10a–v using guanidine
hydrochloride in alcoholic NaOH medium under reﬂuxingdine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
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Scheme 1 Synthetic route for indole based pyrimidine hybrids, Reagents and conditions: (a) HCl, NaNO2, SnCl2, 5 C to RT O/N. (b)
Ethyl pyruvate, cat. HOAc, EtOH, 80 C 1 h. (c) PPA, Toluene, 100 C, 5 h. (d) K2CO3, n-TBAB, DMF, MeI, RT, 12 h. (e) LiOH,
MeOH:THF, RT, 3 h. (f) HATU, DIPEA, cyclopropylamine, DMF, RT, 16 h. (g) DMF, POCl3, 5 to 60 C, 2 h, H2O. (h) NaOH,
substituted acetophenones, EtOH, RT, 2 h. (i) Guanidine hydrochloride, NaOH, EtOH, 80 C, 12 h.
Synthesis and evaluation of indole-pyrimidine hybrids 11condition. A library of twenty-two new compounds were syn-
thesized by following the above mentioned procedure. All the
reactions were monitored using thin layer chromatography
and all the newly synthesized compounds were puriﬁed either
by recrystallization or by column chromatographic techniques.
The structures of all the synthesized intermediates and ﬁnal
compounds were established by various spectral techniques
viz. 1H NMR, 13C NMR, mass spectrometry and elemental
data. Intermediates 6a/6b were conﬁrmed by the formation
of broad peaks in the range of d 12.4–12.1 ppm in their 1H
NMR spectra which corresponds to the –OH proton. In the
13C NMR spectrum, the AC‚O carbon of –COOH group
in 6a and 6b resonates at d 163.5 and 162.8 ppm, respectively.
The amide –NH in intermediates 7a/7b appears as a singlet at
around d 8.47 ppm in the 1H NMR spectrum. Further, the
four aliphatic protons of the cyclopropyl ring appear as a mul-
tiplet whereas the junction –CH of the cyclopropyl ring gives a
multiplet due to coupling with the neighbour protons. In the
13C NMR spectra of 7a and 7b, the methylene carbon of
the cyclopropyl ring appears at around d 6.2 ppm whereas
the junction carbon resonates at around d 23.1 ppm. The
formylation at position-3 of the indole ring was clearly estab-
lished by the disappearance of an aromatic proton and the
appearance of a new sharp singlet at around d 9.92 ppm (due
to –CHO group) in the 1H NMR spectra of 8a and 8b. The
presence of –CHO group was further conﬁrmed by the appear-
ance of a peak at around d 184.0 ppm in their 13C NMR spec-
tra. Subsequent conversion of these formylated intermediates
into different chalcones 9a–v was also conﬁrmed by NMR
spectral studies. The oleﬁnic protons in these chalcones res-
onate as two distinct doublets with the coupling constant (J)
value in the range of 15.4–15.8 Hz. Also, these alkenyl protons
appear in the downﬁeld region (d 7.9–7.5 ppm) of the
spectrum. Both of these evidences strongly indicate that the
hydrogens of the oleﬁn have attained trans (E) conﬁguration.
In addition, the absence of a proton peak corresponding to
the aldehydic group further supports the formation ofPlease cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
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diates (9a–v) to their corresponding target compounds 10a–v
was conﬁrmed in the 1H NMR spectrum by the formation of
a new singlet peak in the range of d 6.64–6.80 ppm owing to
the presence of an amino group. Moreover, the complete dis-
appearance of peaks due to oleﬁnic protons also supports
the proposed ﬁnal structure of these molecules. The chemical
structure of all the ﬁnal molecules was further established by
their 13C NMR spectra. Additionally, the mass spectra are also
in analogy with the structural molecular mass giving M+H
peak viz. in the positive mode. The complete analytical and
spectral data of all the intermediates and title compounds
are discussed in the experimental section and their physical
data are presented in Table 1.
4.2. Anti-proliferative studies
The synthesized compounds were evaluated for their ability to
inhibit the growth of HepG2 (hepatocellular liver carcinoma),
MCF-7 (human breast adenocarcinoma), HeLa (human cervi-
cal adenocarcinoma) and the non-tumourigenic Vero (African
green monkey kidney epithelial cells) cell lines using the MTT
assay [36]. The in vitro antiproliferative activity results are
summarized in Table 2. MCF-7 and HepG2 cell lines were
found to be sensitive as most of the synthesized compounds
displayed higher growth inhibition on these two cells. Those
compounds which inhibit the cancer cell growth to 70% or
more could be considered as highly potent agents. Nature of
substituents and the structural features aided us in deducing
the structure-activity relationship (SAR). In accordance, it
was found that compounds 10f, 10o and 10v were the most
active as they portrayed highest cytotoxic activity against all
the three cell lines. They also depicted superior activity as com-
pared to standard Doxorubicin and were twice as potent when
compared to 5-Fluorouracil. Compounds 10f and 10v have an
electron releasing methyl substitutent at the para (4-Me) and
meta position (3-Me) of the phenyl ring (R2) attached toine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Table 1 Physical data of the target compounds (10a–v).
Code R1 R2 Molecular formula Molecular weight Nature of compound Melting point (C) Yield (%)
10a H H C23H21N5O 383.45 Oﬀ-white solid 118–119 91
10b H 4-F C23H20FN5O 401.44 Oﬀ-white solid 105–106 75
10c H 4-Cl C23H20ClN5O 417.89 Pale yellow solid 125–126 82
10d H 4-Br C23H20BrN5O 462.34 Yellow solid 121–122 73
10e H 4-OMe C24H23N5O2 413.47 Pale yellow solid 95–96 90
10f H 4-Me C24H23N5O 397.47 Yellow solid 126–127 87
10g H 3-F C23H20FN5O 401.44 Yellow solid 108–109 91
10h H 3-Cl C23H20ClN5O 417.89 Oﬀ-white solid 163–164 81
10i H 3-Br C23H20BrN5O 462.34 Pale yellow solid 110–111 68
10j H 3-OMe C24H23N5O2 413.47 Pale yellow solid 115–116 76
10k H 3-Me C24H23N5O 397.47 Oﬀ-white solid 125–126 80
10l F H C23H20FN5O 401.44 Oﬀ-white solid 129–130 87
10m F 4-F C23H19F2N5O 419.43 Oﬀ-white solid 115–116 83
10n F 4-Cl C23H19ClFN5O 435.88 Brown solid 187–188 75
10o F 4-Br C23H19BrFN5O 480.33 Yellow solid 189–190 76
10p F 4-OMe C24H22FN5O2 431.46 Pale yellow solid 118–119 82
10q F 4-Me C24H22FN5O 415.46 Oﬀ-white solid 124–125 90
10r F 3-F C23H19F2N5O 419.43 Oﬀ-white solid 111–112 80
10s F 3-Cl C23H19ClFN5O 435.88 Oﬀ-white solid 115–116 84
10t F 3-Br C23H19BrFN5O 480.33 Yellow solid 140–141 61
10u F 3-OMe C24H22FN5O2 431.46 Pale yellow solid 117–118 59
10v F 3-Me C24H22FN5O 415.46 Oﬀ-white solid 106–107 81
Table 2 Cytotoxicity of compounds 10a–v against three human cancer cell lines (at 10 lM) and against noncancerous Vero cell line
(at 50 lM).
Compound code % Growth-inhibitory activity a
HeLa HepG2 MCF-7 Vero
10a 32.59 ± 0.3 64.47 ± 1.7 68.29 ± 1.4 –
10b 21.28 ± 2.4 88.33 ± 1.6 82.00 ± 0.6 –
10c 62.25 ± 3.7 90.62 ± 0.3 81.69 ± 0.6 10.46 ± 2.6
10d 40.85 ± 6.8 70.29 ± 1.1 59.80 ± 1.7 –
10e 27.98 ± 1.0 48.87 ± 0.6 31.77 ± 0.6 –
10f 70.60 ± 1.9 93.80 ± 0.1 86.97 ± 0.4 12.76 ± 3.4
10g 62.78 ± 2.5 77.29 ± 1.4 71.53 ± 3.6 15.03 ± 2.1
10h 28.68 ± 2.6 81.88 ± 0.6 72.39 ± 0.9 –
10i 30.49 ± 0.3 50.35 ± 0.6 37.35 ± 2.3 –
10j 21.76 ± 0.2 40.72 ± 1.3 34.91 ± 1.9 –
10k 62.04 ± 1.6 82.80 ± 2.0 82.98 ± 0.1 –
10l 13.35 ± 2.7 56.34 ± 1.1 46.63 ± 1.9 –
10m 14.35 ± 4.0 42.65 ± 0.6 33.74 ± 4.2 –
10n 9.63 ± 2.3 7.94 ± 2.5 10.06 ± 0.5 –
10o 82.51 ± 0.5 91.97 ± 1.9 86.91 ± 0.4 17.28 ± 0.3
10p 15.30 ± 6.5 49.94 ± 1.1 20.73 ± 0.5 –
10q 14.35 ± 0.8 84.16 ± 3.2 79.17 ± 2.7 –
10r 21.58 ± 2.8 77.41 ± 0.6 75.09 ± 1.5 –
10s 35.68 ± 4.4 76.59 ± 2.2 71.49 ± 1.8 –
10t 46.44 ± 1.9 81.38 ± 1.6 56.40 ± 1.4 –
10u 60.99 ± 1.2 93.95 ± 0.2 90.02 ± 0.1 8.87 ± 1.4
10v 80.59 ± 0.9 93.31 ± 0.3 89.65 ± 0.1 22.97 ± 3.4
Doxorubicin 77.1 ± 2.4 65.3 ± 0.8 88.1 ± 0.3 46.1 ± 0.1
5-Fluorouracil 45.0 ± 3.3 42.0 ± 0.8 35.0 ± 2.2 22.1 ± 3.0
– Not determined.
The % growth inhibition values > 70 are highlighted in bold.
a All values are expressed as mean ± SEM (n= 3). Experiment was performed in triplicate.
12 N. Gokhale et al.pyrimidine unit respectively whereas compound 10o comprises
of bromo substituent at R2. However, compounds 10k (3-Me)
and 10q (4-Me) at R2 have displayed selective cytotoxic inhibi-Please cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimi
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.003tion on HepG2 and MCF-7 cells. Also, methoxy groups (at
R2) did not impart much activity except for compound 10u
(3-OMe). In terms of compounds with electron attractingdine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
Table 3 Anti-microbial activity of the compounds (10a–v) at a concentration of 10 lg/disc.
Compound codes Zone of inhibition in mm
Antibacterial activity Antifungal activity
S. aureus B. subtilis E. coli P. aeruginosa C. albicans A. niger
10a 09 10 08 10 10 10
10b 24 26 27 25 24 25
10c 26 26 28 26 27 27
10d 18 19 17 16 19 18
10e 08 09 10 11 10 09
10f 08 08 09 10 09 08
10g 29 28 25 27 25 26
10h 24 25 25 24 24 25
10i 20 21 20 18 20 20
10j 08 08 09 08 10 10
10k 12 14 13 15 14 13
10l 16 14 18 14 15 15
10m 28 26 25 25 26 25
10n 27 28 28 26 27 27
10o 19 20 20 22 23 21
10p 14 16 16 18 16 19
10q 20 21 20 22 21 23
10r 28 26 27 26 24 25
10s 24 26 22 25 26 24
10t 18 17 20 23 20 19
10u 16 15 18 16 17 15
10v 20 21 21 20 18 17
Ciproﬂoxacin 27 26 28 25 – –
Flucanazole – – – – 27 26
The % growth inhibition values > 70 are highlighted in bold.
Synthesis and evaluation of indole-pyrimidine hybrids 13groups, compounds 10b, 10g and 10r with ﬂuoro substitution
(R2) and compounds 10c, 10h and 10s with chloro substitution
(R2) showed selective inhibition on HepG2 and MCF-7 cells
whereas 10d and 10t having bromo group (R2) exhibited cyto-
toxicity only on HepG2 cells. Unsusbstituted hybrids (R2), 10a
and 10l have not shown much activity, signifying the need of a
substitution on the phenyl ring for enhanced activity. These
data also suggest that in the case of compounds 10a–10k
(R1 = H), R2 substitution at position-4 and in compounds
10l–10v (R1 = F), R2 substitution at position-3 of the phenyl
ring have aided in improving the cytotoxic activity. It is also
worthy to mention that all the active compounds displayed
negligible growth inhibition on Vero cells indicating their
non-toxic nature. The synthesized molecules can be further
investigated to develop potential leads since majority of the
active molecules are more potent as compared to the positive
control drugs, Doxorubicin and 5-Fluorouracil.
4.3. Anti-microbial studies
The antimicrobial activity was determined using the disc
diffusion method [33] by measuring the zone of inhibition in
millimetre (mm). All the compounds (10a–u) were screened
in-vitro at a concentration of 10 lg/disc for their antibacterial
activity against two Gram-positive strains (Staphylococcus
aureus and Bacillus subtilis) and two Gram-negative strains
(Escherichia coli and Pseudomonas aeruginosa). The antifungal
evaluation was carried out against Candida albicans and Asper-
gillus niger at a concentration of 10 lg/disc. Standard antibac-
terial drug ciproﬂoxacin (10 lg/disc) and antifungal drugPlease cite this article in press as: N. Gokhale et al., Facile synthesis of indole-pyrimid
nal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.09.003ﬂuconazole (10 lg/disc) were also tested under similar condi-
tions against these organisms. All the synthesized compounds
exhibited signiﬁcant antibacterial and antifungal activities.
Each experiment was performed in triplicate and the average
reading was taken (Table 3). The activity was classiﬁed as
highly active (P26 mm), moderately active (11–25 mm) and
least active (<11 mm). In view of the values obtained, com-
pounds 10b, 10c, 10g, 10h, 10m, 10n, 10r and 10s are the most
potent in the series. All of these active compounds contain a
substituted phenyl ring attached to the pyrimidine unit (R2).
Remaining molecules displayed either moderate or weak inhi-
bition activity. The active molecules depict a trend wherein
halogen substitutions mainly consist of ﬂuoro or chloro groups
at either position-3 or 4 of the phenyl ring. On the other hand,
bromo, methoxy and methyl groups did not impart much
enhancement in the activity. Furthermore, an overall compar-
ison between compounds 10a–10k and 10l–10v hints at slightly
improved activity of the latter set which may be due to the
presence of bioisostere ﬂuoro group on the indole core (R1).
It can also be seen that the potency of the active molecules is
comparable with that of the standard drugs (Table 3).
5. Conclusions
The paper describes the synthesis of a new library of indole-3-
pyrimidine hybrids consisting of an amide linkage at position-2
of the indole ring and a diversely substituted phenyl ring on the
pyrimidine moiety. The structural identiﬁcation of all the
intermediates and target compounds was carried out by spec-
troscopic techniques namely 1H NMR, 13C NMR, ESI–MSine hybrids and evaluation of their anticancer and antimicrobial activity, Jour-
14 N. Gokhale et al.and elemental analyses. The target molecules were investigated
for their in vitro anti-proliferative and antimicrobial properties
by MTT assay and disc diffusion methods respectively. The
most susceptible cell lines comprised of HepG2 and MCF-7
with the majority of compounds showing higher inhibition
against these cell lines. Compounds 10f, 10o and 10v inhibit
signiﬁcantly the growth of all three cancerous cells indicating
their broad spectrum anti-tumour activity. On the other hand,
in the case of anti-microbial studies, compounds 10b, 10c, 10g,
10h, 10m, 10n, 10r and 10s which contain a chloro or ﬂuoro
substitution (R2) at either position-3 or 4 of the phenyl ring
displayed higher potency than the rest of the molecules. More-
over, low toxicity on the benign Vero cells and higher efﬁcacy
of the active molecules may provide a potential lead for the
development of novel therapeutic agents in future.Acknowledgements
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